Spots Global Cancer Trial Database for Hypofractionated Radiation Therapy With Concomitant Boost in Treating Women After Breast Conserving Surgery

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Hypofractionated Radiation Therapy With Concomitant Boost in Treating Women After Breast Conserving Surgery

Official Title: Phase II Trial of Hypofractionated Whole-breast Radiation and Concomitant Boost to the Surgical Bed After Breast Conserving Surgery

Study ID: NCT03320421

Conditions

Breast Cancer Female

Interventions

Radiation therapy

Study Description

Brief Summary: This phase II study is to evaluate the safety of hypofractionated whole breast radiation (HFRT) with simultaneous tumor bed boost(SIB) in women with early breast cancer after breast-conserving surgery.

Detailed Description: OBJECTIVES: Primary: To determine the toxicity with adjuvant hypofractionated whole breast radiation with simultaneous tumor bed boost (SIB) in women with early breast cancer after breast conserving surgery. Secondary: To determine the short term cosmetic and quality of life of the participants treated with this regimen. To determine the local control of the participants treated with this regimen. OUTLINE: Patients undergo adjuvant hypofractionated whole breast radiation with simultaneous tumor bed boost once daily a week for 3 weeks. Toxicity, quality of life and cosmetic result is assessed before radiation, at the end of the radiation, within 2, 4, 6 weeks after completion of radiotherapy, and then every 3 months for 1 ear. PROJECTED ACCRUAL: A total of 90 participants will be accrued for this study.